Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC) Meeting Abstract
| Authors: | Rugo, H. S.; Bardia, A.; Im, S. A.; Simon, S. P.; De Laurentiis, M.; Wang, S.; Martinez, N.; Borges, G. S.; Cescon, D.; Hattori, M.; Lu, Y. S.; Tsurutani, J.; Tolaney, S. M.; Mapiye, D.; Atuah, K.; Verma, D.; Khan, S.; Xu, B.; Pistilli, B.; Jhaveri, K. |
| Abstract Title: | Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S400 |
| End Page: | S401 |
| Language: | English |
| ACCESSION: | WOS:001326612900426 |
| DOI: | 10.1016/j.annonc.2024.08.378 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 431P -- Source: Wos |
